A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

NCT02720523 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Placebo
DRUG: Upadacitinib

Sponsor

AbbVie